Clinical Trials Logo

Muscular Dystrophies clinical trials

View clinical trials related to Muscular Dystrophies.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06274983 Active, not recruiting - Clinical trials for Duchenne Muscular Dystrophy

DMD- Interactive Virtual Reality Study

DMD-IVR
Start date: April 20, 2023
Phase: N/A
Study type: Interventional

This study will help determine if an Interactive Virtual Reality system can improve the physiotherapy of young patients with Duchenne muscular dystrophy (DMD).

NCT ID: NCT06241950 Active, not recruiting - Clinical trials for Duchenne Muscular Dystrophy

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Start date: January 29, 2024
Phase: Phase 1
Study type: Interventional

This is a gene transfer therapy study evaluating the safety of delandistrogene moxeparvovec and delandistrogene moxeparvovec dystrophin expression in association with imlifidase, in participants with DMD with pre-existing antibodies to rAAVrh74 over a period of 104 weeks.

NCT ID: NCT05989620 Active, not recruiting - LGMD2I Clinical Trials

Long-Term Development of Muscular Dystrophy Outcome Assessments

GRASP-01-005
Start date: October 18, 2023
Phase:
Study type: Observational

This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).

NCT ID: NCT05906251 Active, not recruiting - Clinical trials for Limb Girdle Muscular Dystrophy

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)

Start date: May 22, 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of SRP-6004 administered by intravenous (IV) infusion in ambulatory participants with LGMD2B/R2 (DYSF related).

NCT ID: NCT05876780 Active, not recruiting - Clinical trials for Limb Girdle Muscular Dystrophy

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Start date: December 19, 2022
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of SRP-9003 and to quantify expression of β-SG in the skeletal muscle of participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). The study will include both ambulatory (Cohort 1) and non-ambulatory (Cohort 2) participants.

NCT ID: NCT05661071 Active, not recruiting - Clinical trials for Duchenne Muscular Dystrophy

Neuropsychological Profiles of Children With Duchenne Muscular Dystrophy and Its Effects on Motor Functions

Start date: May 11, 2022
Phase:
Study type: Observational

This study was planned to determine neuropsychological profiles of children with Duchenne Muscular Dystrophy and investigation of its effects on motor functions & compare to typically developed peers.

NCT ID: NCT05548556 Active, not recruiting - Clinical trials for Facioscapulohumeral Muscular Dystrophy (FSHD)

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

MANOEUVRE
Start date: February 7, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

NCT ID: NCT05514249 Active, not recruiting - Clinical trials for Duchenne Muscular Dystrophy

Treatment of a Single Patient With CRD-TMH-001

Start date: August 31, 2022
Phase: Phase 1
Study type: Interventional

The study is a single patient study intended to understand the effects of a gene-editing therapeutic to treat a rare mutation of Duchenne muscular dystrophy.

NCT ID: NCT05479981 Active, not recruiting - Clinical trials for Nervous System Diseases

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

MARINA-OLE
Start date: August 4, 2022
Phase: Phase 2
Study type: Interventional

AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients

NCT ID: NCT05429372 Active, not recruiting - Clinical trials for Muscular Dystrophy, Duchenne

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Start date: August 8, 2022
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study